医薬品リファレンス
Brentuximab vedotin
Brentuximab vedotin is a medicine in the class oncology. It is used for b-cell lymphoma.
- 薬効分類: Oncology
- 効能・効果: b-cell lymphoma
最終更新日 出典: US FDA label, EMA SmPC
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01FX05
- 一般的な剤形
- 注射剤
- 一般的な規格
- 50 mg/10.5 ml
- 既知の相互作用
- 24 (併用禁忌: 1 · 重大: 1 · 中等度: 13 · 軽度: 9)
- 商品名
- 2
- 国・市場
- 2
何に使われるか
作用のしくみ
CD30-directed antibody-drug conjugate: a chimeric IgG1 linked to the microtubule-disrupting agent MMAE. After binding CD30-expressing cells and internalization, MMAE is released and binds tubulin, causing cell cycle arrest and apoptosis.
成人の通常用量（添付文書の要約）
Monotherapy for adults: 1.8 mg/kg up to a maximum of 180 mg, intravenous infusion over 30 minutes, every 3 weeks
妊娠と授乳
- 妊娠
- Unsafe Antibody-drug conjugate (cytotoxic MMAE): can cause fetal harm. Avoid in pregnancy. Women: effective contraception during treatment and for 2 months after; men with female partners: 4 months.
- 授乳
- Unsafe No human milk data. Avoid breastfeeding during treatment because of possible serious infant harm (low blood counts, nerve or gut toxicity).
報告されている副作用
- Peripheral neuropathy
- Nausea
- Fatigue
- Musculoskeletal pain
- Constipation
- Diarrhea
警告（枠囲み警告）
- JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in patients receiving ADCETRIS.
禁忌
- Concomitant use with bleomycin due to pulmonary toxicity
注意が必要な方
- Peripheral neuropathy is cumulative, predominantly sensory; monitor and modify dose, delay or discontinue.
- Anaphylaxis and infusion reactions: monitor during infusion; permanently discontinue for anaphylaxis.
- Hematologic toxicities including fatal febrile neutropenia; monitor CBC before each dose; G-CSF primary prophylaxis in combination regimens.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (24)
- Bleomycin + Brentuximab vedotin Contraindicated
- Brentuximab vedotin + Siponimod Major
- Apalutamide + Brentuximab vedotin Moderate
- Brentuximab vedotin + Clarithromycin Moderate
- Brentuximab vedotin + Imatinib Moderate
- Brentuximab vedotin + Isoniazid Moderate
- Brentuximab vedotin + Itraconazole Moderate
- Brentuximab vedotin + Ketoconazole Moderate
- Brentuximab vedotin + Mifepristone Moderate
- Brentuximab vedotin + Posaconazole Moderate
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Brentuximab vedotinの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
- IV preparation and dilution
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Brentuximab vedotin used for?
Brentuximab vedotin is a medicine in the class oncology. It is used for B-cell lymphoma, Hodgkin lymphoma, Lymphoma.
What side effects have been reported with Brentuximab vedotin?
Peripheral neuropathy, Nausea, Fatigue, Musculoskeletal pain, Constipation, Diarrhea. Serious warning: JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in patients receiving ADCETRIS.
Can Brentuximab vedotin be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Antibody-drug conjugate (cytotoxic MMAE): can cause fetal harm. Avoid in pregnancy. Women: effective contraception during treatment and for 2 months after; men with female partners: 4 months. Breastfeeding: Unsafe. No human milk data. Avoid breastfeeding during treatment because of possible serious infant harm (low blood counts, nerve or gut toxicity).
What does Brentuximab vedotin interact with?
MediHelp lists 24 known interactions for Brentuximab vedotin. Contraindicated: 1 · Major: 1 · Moderate: 13 · Minor: 9. The most serious include Bleomycin, Siponimod, Apalutamide.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
